New drug duo targets hard-to-treat HER2 cancers in groundbreaking trial
NCT ID NCT07243938
First seen Jan 06, 2026 · Last updated May 01, 2026 · Updated 21 times
Summary
This study tests two drugs, zanidatamab and tislelizumab, together with chemotherapy or radiation for people with HER2-positive gastrointestinal cancers like rectal, stomach, and colon cancer. About 70 adults will receive the treatment to see if it can shrink tumors before surgery or control advanced disease. The goal is to improve outcomes while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.